

SUBJECT INDEX

- A**
- Acetaminophen
 - hepatotoxicity induced by, 48, 55
 - reactive metabolites of, 20, 28
 - Acetylcholine
 - binding pocket models, 435, 439-40
 - botulinum and, 2
 - early studies, 1-3, 6
 - nicotinic receptors
 - See Nicotinic acetylcholine receptors
 - physical chemistry of binding, 437-38
 - Acivicin, 31
 - Adenosine 5'-triphosphate (ATP)
 - P2X receptors and, 563-75
 - Adenylate cyclase (AC)
 - activity
 - 5-ht₆ receptor and, 321
 - regulation by opioids, 390-93
 - Aflatoxin, 48
 - AIDS
 - dual protease inhibitor therapy for HIV infection, 651-72
 - Alcohols
 - sulfation of, 164
 - Allostery, 444-48
 - Allyl formate, 48
 - Alzheimer's disease
 - 5-ht₆ receptors and, 329
 - Amprenavir, 651, 653-55, 666-68
 - Anabolic steroids, 24
 - Angiogenesis, 295, 303-4
 - vascular endothelial growth factor and, 303-4
 - Antipsychotic medication
 - potential
 - 5-ht₆ receptors, 319, 322-24, 328-30
 - Antisense, 319, 327-28, 330
 - Apolipoprotein E
 - cholesterol levels and, 105
 - Apoptosis
 - 14-3-3 proteins and, 617, 629-32
 - hypoxia-induced, 529
 - mitochondrial bioenergetics and, 353
 - Rho and, 472-73
 - Aryl hydrocarbon (Ah) receptor pathway
 - PAS domain and, 521-27, 537
 - Ascorbic acid synthesis, 23-24
 - Atabrine, 20
 - ATP-synthetase inhibitors, 364
 - Autoimmunity
 - autoimmune hepatitis, 605-6
 - UDP-glucuronosyltransferases and, 581, 605-6
 - Automation, 203
- B**
- Bayes theory, 72
 - Bioenergetics
 - apoptosis and, 353
 - cell signaling and, 353
 - mitochondrial, 353-78
 - Bioinformatics, 97, 120, 177, 182, 188
 - Biotransformation
 - chemical-induced hepatotoxicity and, 48
 - Blood-brain barrier
 - drug-candidate screening and, 141
 - Botulinum, 1-2
 - Branched-DNA signal amplification, 337-38, 347-49
 - Bromobenzene, 48
 - Bromotrichloromethane, 48, 49
- C**
- Caco-2, 133-41, 143
 - permeability screening for, 133, 139-41
 - automation and, 139-40
 - immobilized artificial membrane (IAM) chromatography, 140
 - parallel artificial membrane permeation assay, 140
 - Cancer
 - UDP-glucuronosyltransferases and, 581, 603-5
 - Carbonic anhydrase, 1
 - Carbon tetrachloride, 43-55
 - hepatotoxic properties of, 43, 45, 51
 - liver injury, 43-55
 - biotransformation and, 48
 - free radicals and, 48-49
 - lipid peroxidation and, 49-50
 - potentiation, 50-53
 - sympathetic nervous system and, 46-49
 - Carcinogenesis
 - UDP-glucuronosyltransferases and, 603-5

- Cathepsin K, 193, 197–99,
202
osteoporosis treatment,
197–99
- Cell adhesion
selectins and
myocardial injury and,
283–91
- Cell cycle
14-3-3 proteins and, 617
- Cell growth
hypertrophic
Rho and, 472
- Cell migration
Rho and, 468–69
- Cell proliferation
Rho and, 471
- Cell signaling
mitochondrial bioener-
getics and, 353
- Cheminformatics, 177, 184–
85, 188
- Chlordecone, 52
- Chlorinated methanes
carbon tetrachloride, 43
chloroform, 43
liver injury and, 43
mechanism of action, 45
- Chloroform, 43, 48–55
biotransformation and, 48
free radicals, 48–50
hepatotoxic properties of,
43, 45
lipid peroxidation and, 49–
50, 55
potentiation, 50–53
- Circadian rhythms
PAS domains and, 519,
533–37
- Clinical trials simulation
See Computer simulation
clinical trials
- Clozapine, 321, 326, 330
- Cognition
5-HT₁ receptors and, 319,
322–24, 328–29
anxiety, 328, 330
depression, 328, 330
dysfunctions, 329–30
memory disorders, 328–
30
potential therapeutic
indications, 329–30
- Combination therapy, 658–
59
- Combinatorial chemistry,
177, 182, 188, 202,
273–79
mixture-based, 273–79
parallel array synthesis
approaches, 273–75,
278–79
- Computer simulation clinical
trials, 209–31
good practices, 213–14
simulation models, 215–17
software, 217–19
- Conformation
muscarinic receptor, 1, 6–
8, 10–12
NMR studies of, 6–12
- Creutzfeld-Jakob disease,
636
- Crigler-Najjar syndrome,
581, 600–1
- Cytochrome *c* oxidase
(COX) inhibitors, 355,
362–64
- Cytochrome *c* oxidoreduc-
tase, 360
- Cytochrome P450
drug-candidate screening
and, 133, 141–44, 150
enzymes
deuterium isotope
effects, 32–33
mechanisms of, 31–33
induction, 143–44
inhibition, 141–43, 649,
653, 655, 659–61, 664–
65
dual protease inhibitors,
649, 653, 655, 659–61,
664–65
superfamily, 118–19
drug metabolism and,
118–19
- Cytoskeleton, 459, 464–66
actin
Rho and regulation of,
464–66, 469, 474
- Cytotoxicity
inhibitors, 357–64, 378
uncouplers, 353–54, 365–
78
- D**
- Deconvolution, 273, 276,
278
iterative, 273, 276, 278
- Detoxification
glucuronidation, 581–606
- Differential displays, 338–39
- Dihydrofolate reductase
(DHFR), 1, 11–12
- Dimethylnitrosamine, 48
- 2-4-Dinitrophenol, 366–67,
371
- Dioxin
aryl hydrocarbon receptor
pathway and, 519, 521–
27
- DNA sequence variation
single nucleotide polymor-
phism (SNP) and, 97,
102–18
- Dopamine
sulfation of, 164
- Down's syndrome
comparative genomics
and, 122–23
- Drug action targets, 1–14
atypical sensitivity and, 10
muscarinic receptor speci-
ficity and, 6–14
- Drug atypical sensitivity, 10
- Drug candidate screening
absorption potential
assessment, 139–41
Caco-2 permeability
and, 139–41, 143
biotransformation, 147–49

- blood-brain barrier, 141
- computer modeling, 149–50
- counterscreens, 136
- criteria, 135–36
- cytochromes P450, 141–44, 150
 - induction, 143–44
 - inhibition, 141–43
- drug metabolism and, 133, 135–51
- interpretation, 137
- pharmacokinetics and, 133, 135–51
- See also High-throughput screening; Screening
- Drug design, 1–14
 - receptor specificity and, 6–14
- Drug development
 - computer simulation clinical trials, 209–31
 - good practices, 213–14
 - simulation models, 215–17
 - software, 217–19
- dual protease inhibitors and, 671
- modeling and, 67–90
 - definition, 68
 - examples, 80–87
 - exchangeability, 75–76
 - informative deviations, 77–78
 - learn-confirm cycles, 67, 69–71
 - marginal versus conditional, 76–77
 - pharmacokinetic/pharmacodynamic, 67–68, 72–90
 - uses, 78–80
- Drug discovery
 - cheminformatics, 177, 184–85, 188
 - combinatorial chemistry, 177, 182, 188, 202, 273–79
 - mixture-based, 273–79
 - parallel array synthesis approaches, 273–75, 278–79
 - gene therapy, 177, 186–88
 - genomics and, 177, 185–86, 188, 193–205
 - automation, 203
 - cathepsin K, 193, 197–99, 202
 - combinatorial chemistry, 202
 - expressed sequence tags (EST) sequencing, 193–99, 205
 - functional, 177, 185–86, 188
 - high-throughput screening and, 193–205
 - microarrays, 193, 203–4
 - novel protein sequences, 196–97
 - “smart” libraries, 194–96
 - target validation, 193–205
 - high-throughput screening, 133–51, 177, 180–84, 188, 193–205
 - 5-HT₆ receptors and, 319–30
 - antipsychotic medication potential, 319, 322–24, 238–30
 - medicinal chemistry, 182–83
 - protein therapeutics, 186–88
 - proteomics, 177, 179–80, 188, 193, 204–5
 - target validation, 177–79, 188, 193–205
 - toxicity evaluation
 - branched DNA signal amplification, 337–38, 347–49
 - differential displays, 337–39
 - hybridization microarrays, 335, 337, 340–46
 - real-time polymerase chain reaction (RT-PCR), 335, 337, 347–49
 - scintillation proximity, 337–38, 347–49
 - serial analysis of gene expression (SAGE), 337–38, 346–47
 - subtractive hybridization, 337, 339–40
- Drug interactions
 - HIV protease inhibitors and, 649, 653–56
- Drug metabolism
 - cytochrome P450 and, 118–19, 141–44, 150
 - drug candidate screening and
 - biotransformation and, 147–49
 - computer modeling, 149–50
 - cytochrome P450, 141–44, 150
 - drug concentration in blood, 19–20
 - metabolites
 - deuterium isotope effects, 32–33
 - drug-candidate screening and, 147–49
 - drug-metabolizing enzymes, 22–23
 - immune responses to, 33–34
 - kinetics of drug metabolism in perfused organs and, 25–26
 - renal toxicity and, 31
 - suicide enzyme inhibitors, 31–32
 - toxic chemically reactive, 19–20, 27–34
 - pharmacogenetics and, 97, 118–20

- Drug screening
 See Drug candidate screening, High-throughput screening, Screening
- Drug toxicity
 mitochondrial targets of, 353-78
- Dual protease inhibitors, 649-70
- amprenavir, 651, 653-55, 666-68
- HIV, 649-70
- impact on clinical treatment of, 664-66
- indinavir, 650-56, 661-63, 665-68
- lopinavir, 669
- metabolic drug interactions and, 655-56
- nelfinavir, 650-55, 663-69
- ritonavir, 650-55, 657-69
- saquinavir, 650-60, 665-68
- Duchenne muscular dystrophy, 300-1
- cell therapy for, 300-1
- E**
- Ecosanoids
 sulfation of, 164
- Electrochemical proton gradient, 354-56
- Endoplasmic reticulum
 liver injury
 chlorinated methanes and, 43-45
- Endothelium
 myocardial injury and, 283-91
- nitric oxide and, 284, 289-90
- selectins and, 283-91
- cell adhesion cascade of inflammation and, 284, 290-91
- Epoxides, 27, 32
- Erythropoietin-responsive anemias, 302-3
- Estrogen
 sulfation of, 164
- N-Ethyl-N-nitrosourea, 186
- Expressed sequence tags (ESTs), 193-99, 205
- Extrahepatic
 See UDP-glucuronosyl-transferase, extrahepatic
- F**
- 14-3-3 proteins, 617-38
- antagonists, 637
- Creutzfeldt-Jakob disease and, 636
- isolated lissencephaly sequence (ILS), 636
- ligand interactions, 624-28
- Miller-Dieker syndrome (MDS), 636
- phosphoserine-mediated interactions, 617, 624-25
- properties, 618
- regulation of, 634-36
- regulation of intracellular signaling, 626-34
- Free radicals, 48-50, 55, 353
- carbon tetrachloride-derived, 49-50, 55
- chemical-induced hepatotoxicity and, 48-50
- Furosemide, 48
- G**
- $G\alpha_{12/13}$, 459, 472, 475-76
- GABA_A receptors, 431-32, 435, 442
- GABA_C receptors, 431-32
- Gene regulation
- tetracycline-inducible retroviral vectors and, 305-7
- Gene therapy, 177, 186-87, 295-311
- ex vivo approaches, 296
- in vivo approaches, 296
- muscle stem cell, 307, 309
- myoblast-mediated, 295-311
- Duchenne muscular dystrophy and, 300
- encapsulation of myoblasts and, 310-11
- ex vivo gene delivery, 296-305
- secretable factors gene delivery, 301-5, 309-11
- tetracycline-inducible retroviral vectors, 295, 305-9
- Gene transcription
- Rho and, 469-71, 474
- Genomics, 97-125
- chimpanzee, 123-24
- comparative, 97, 120-23
- synteny, 121-23
- drug discovery and, 193-205
- automation, 203
- cathepsin K, 193, 197-99, 202
- combinatorial chemistry, 202
- expressed sequence tags (EST) sequencing, 193-99
- high-throughput screening, 193-205
- microarrays, 193, 203-4
- novel protein sequences, 196-97
- pharmacogenetics and, 97, 118, 120
- proteomics, 193, 204-5
- "smart" libraries, 194-96
- target validation, 193-205
- drug screening
- See Drug candidate screening; High-throughput screening; Screening
- functional, 177-89
- human, 97-125

- comparative genomics, 97, 120–23
 - evolution and, 124
 - synteny and, 121–23
 - limits of, 124–25
 - Gilbert's syndrome, 581
 - Glucuronidation, 581–606
 - carboxylic acid, 595–96
 - gastrointestinal tract, 600–1
 - O-linked, 593
 - N-, 596
 - phenanthrene, 593, 595
 - steroid, 595
 - Glycine receptors, 431, 435, 442
 - P-Glycoprotein, 649
 - Glycoprotein adhesion molecules
 - selectins, 283–91
 - P-Glycoprotein (PGP) efflux pump, 139–41
 - G protein–adenylate cyclase pathway, 390–93
 - G protein–coupled inwardly rectifying K⁺ channels, 240
 - G protein–coupled receptor kinases (GRKs), 235–36
 - G protein–coupled receptors (GPCRs)
 - agonists
 - lysophosphatidic acid (LPA), 459, 463, 465, 467–69, 473
 - thrombin, 459, 465, 468–69, 471
 - cross-reactivity of ligands, 201–2
 - drug discovery targets, 178, 180, 183–85
 - gene superfamily, 199–202
 - melanin-concentrating hormone, 200–1
 - opioid receptors, 389–415
 - orexins, 200–1
 - receptor genes, 405–12
 - receptor phosphorylation, 399–405
 - receptor structure, 389–99
 - See also Opioid receptors
 - G protein–coupled receptor signaling pathways, 235–62
 - regulator of G protein signaling (RGS) proteins and, 235–62
 - cell types, 240–43
 - mechanisms of action, 243–44
 - G protein–coupled signal transduction, 459–78
 - Rho-dependent pathways and, 459–78
 - apoptosis and, 472–73
 - bacterial toxins and, 462–64
 - cell migration and, 468–69
 - cell proliferation and, 471
 - cytoskeleton and, 459, 464–66, 474
 - effectors, 464
 - gene transcription and, 469–71, 474
 - hypertrophic cell growth, 472
 - MAP kinase activation and, 469–71
 - phospholipid metabolism, 462, 466–67
 - regulators, 460–64
 - RhoA, 459–60, 465, 470, 472–74
 - RhoGAPs, 460
 - RhoGDI, 460, 462
 - RhoGEF, 459–61
 - smooth muscle contraction, 467–68, 474
 - tumor cell invasion and, 467–69
 - G proteins, 389–415
 - G protein–adenylate cyclase pathway, 390–93
 - heterotrimeric, 459, 467
 - opioid receptor signaling and, 389–415
 - small, 459
 - See also G protein–coupled receptors; Opioid receptors
 - Growth suppression, 491, 507–8
 - GTPase activating proteins (GAPs), 235–37, 249–62, 460
 - mechanism of activity, 252–55
 - mutagenesis, 254–55
 - Guanine exchange factors, 236
 - Guanine nucleotide dissociation inhibitors (GDIs), 460, 462
 - Guanine nucleotide exchange factors, 460
- ## H
- Halothane, 48, 55
 - Hemophilia B, 302
 - Hepatocarcinogenesis
 - oxidative-stress hypothesis, 504
 - peroxisome proliferator-induced, 495, 497, 504–7
 - Hepatocytes
 - drug screening and, 133, 148
 - Hepatotoxicity
 - biotransformation, 48
 - chlorinated methanes and, 43–56
 - free radicals and, 48–50, 55
 - hepatocellular regeneration and, 43, 53–55
 - lipid peroxidation and, 49–50, 55
 - oxidative stress leading to, 50, 55
 - High-throughput screening (HTS), 133–51, 177,

- 180–84, 188, 193–205,
335, 337
drug discovery and, 193–
205
See also Candidate drug
screening; Screening
HIV infection
dual protease inhibitor
therapy for, 649–70
HMG-1, 180
5HT₃ receptor, 431–32, 435
5-HT₆ receptors
antipsychotic medical
potential, 319, 322–24,
328–30
antisense oligonucleotides,
319, 327–28, 330
cellular responses, 326–27
cholinergic neurotransmis-
sion, 319, 329
knockout mice, 328
learning and memory dis-
orders
treatment potential, 319,
322–24, 328–30
localization of mRNA,
324–25
localization of receptor
protein, 325–26
molecular biology, 320
molecular pharmacology,
320–22
adenylate cyclase and,
319, 321
potential therapeutic indi-
cations, 328–29
selective regulation of
agonists and antagonists,
322–24, 328–29
tissue responses, 327
Human Genome Project, 177
Human genomics, 97–125
comparative genomics, 97,
120–23
synteny and, 121–23
evolution and, 124
limits of, 124–25
microbial pathogens and,
100–2
pharmacogenetics and, 97,
118, 120
See also Genomics
Hypoxia response pathway
apoptosis and, 529
PAS domains and, 519,
527–33, 537
- I**
Immobilized artificial mem-
brane chromatography,
140
Immunology, 19, 33–34
Indinavir, 650–56, 661–63,
665–68
Inflammation
peroxisome proliferator-
activated receptors and,
491, 497–98, 508–9
Inherited unconjugated
hyperbilirubinemia,
601–5
Ion channels
functional organization,
441–43
ligand-gated, 431–48,
563–75
opioid receptors and, 393–
95
P2X receptors, 563–75
structural organization,
440–41
Ionophores, 372–73
Iproniazid, 10
Ischemia/reperfusion injury
selectin inhibitors and,
283–91
monoclonal antibodies,
285–87
selectins, 283–91
sialyl Lewis^x analogs,
288–89
Isolated lissencephaly
sequence, 636
Isoniazid, 10, 48
- K**
Keratinocyte growth factor-1,
187
Ketones, 43
Knockout mice
receptor, 389, 410–12
- L**
Learning and memory dis-
orders
5-HT₆ receptors and, 319,
322–24, 328–29
Libraries
chemical, 337
mixture-based combinato-
rial, 273–76
iterative deconvolution
of soluble, 276
positional scanning syn-
thetic combinatorial, 276,
278–79
Library synthesis, 273–79
Lipid peroxidation, 43, 49–
50
hepatotoxicity and, 43,
49–50
Lipinski's Rule, 149–50, 184
Lipolysis, 25
Lipophilic weak acids, 365–
66
Liver injury
chlorinated methanes and,
43–56
altered sinusoidal circula-
tion and, 46
biotransformation and,
48
endoplasmic reticulum
and, 43–45
free radicals and, 48–50,
55
hepatocellular regenera-
tion, 43, 53–55
lipid peroxidation and,
49–50, 55
mitochondria and, 43–
45

- potentiation of, 50–53
- sympathetic nervous system and, 46–48
- Lopinavir, 669
- LOV domains, 519, 544
- Lysophosphatidic acid (LPA), 459, 463, 465, 467–69, 473
- M**
- Magainin, 273–74
- Malaria
 - cytokines and, 101
 - genomics and, 100–1
 - tumor necrosis factor and, 101
- MAP kinase activation, 469–71
- Melanin-concentrating hormone, 200–1
- Metabolism
 - UDP-glucuronosyltransferases and, 581–606
- Metabolites
 - See Drug metabolism, metabolites; Reactive metabolites
- Methamphetamine, 48
- Microarray gridding (gene-chip), 179
- Microarrays, 193, 203–4, 335, 337, 340–46
- Microbial pathogens, 100–2
 - genomics and, 100–2
 - malaria, 100–2
 - multidrug resistance and, 100
- Miller-Dieker syndrome, 636
- Mitochondria, 353–78
 - bioenergetics, 353–78
 - drug toxicity and, 353–78
 - energy production in, 354–56
 - liver injury
 - chlorinated methanes and, 43–45, 55
 - oxidative phosphorylation, 353–78
 - uncouplers of, 353–54, 357, 365–77
 - poisons, 356–77
 - inhibitors of ATP-synthase, 364
 - inhibitors of respiratory chain, 357–64
 - uncouplers of oxidative phosphorylation, 353–54, 357, 365–77
- Mitogen-activated protein (MAP), 459
- kinase activation, 469–71
- Modeling
 - Bayes theory, 72
 - drug development and, 67–90
 - exchangeability, 75–76
 - informative deviations, 77–78
 - marginal versus conditional, 76–77
 - notation, 71–72
 - pharmacokinetic/pharmacodynamic, 67, 74–90
 - defined, 74
 - statistical, 67–90
- Models
 - descriptive, 69, 75, 76
 - defined, 69
 - deviation from protocol, 73–74
 - empirical, 67, 69–70
 - defined, 69
 - mechanistic, 67, 69–70
 - defined, 69
 - outcome, 74
 - pharmacokinetic/pharmacodynamic, 67, 74–90
 - defined, 74
 - future needs, 88–90
- Molecular toxicology
 - drug screening, 335–50
 - branched DNA signal amplification, 337–38, 347–49
- differential displays, 337–39
- hybridization microarrays, 335, 337, 340–46
- real-time polymerase chain reactions (RT-PCR), 335, 337, 347–49
- scintillation proximity, 337–38, 347–49
- serial analysis of gene expression (SAGE), 337–38, 346–47
- subtractive hybridization, 337, 339–40
- Monoclonal antibodies, 285–87
 - directed against selectins, 285–87
- Monod-Wyman-Changeux theory, 447–48
- Muscarinic receptor, 1–14
 - conformational variability, 1, 6–8
 - early studies, 1–14
 - specificity, 6–14
 - subtypes, 1
- Muscle, 295–311
 - myoblast-mediated gene therapy and, 295–311
 - stem cells, 307, 309
 - See also Myoblast-mediated gene therapy
- Mycobacterium tuberculosis pentameric mechanosensitive receptor from, 443
- Myeloid progenitor inhibitory factor-1, 187
- Myoblast-mediated gene therapy, 295–311
 - Duchenne muscular dystrophy, 296–305
 - encapsulation of myoblasts and, 310–11
 - ex vivo gene delivery, 296–305
 - secretable factors gene delivery, 301–5, 309–11

angiogenesis and, 303–4
erythropoietin-responsive anemias, 302–3
homophilia B, 302
vascular endothelial growth factor, 303–5
Myocardial injury
 selectin and, 283–91
 selectin inhibitors and, 283–91

N

Nelfinavir, 650–55, 663–69
Neuropharmacology, 19, 24–25
NFAT, 248
Nicotinic acetylcholine
 receptors (nAChRs), 431–48
 allosteric transitions of, 444–48
 site for potentiation by Ca^{2+} , 445
Monod-Wyman-Changeux theory, 447–48
nAChR oligomer, 432–33
nicotinic binding
 binding pocket models, 439–40
 pharmacological diversity of sites, 438–39
 physical chemistry of, 437–38
 sites at subunit interface, 436–37
 subunit structure, 433–36
 transmembrane organization, 433–36
Nitric oxide
 endothelium derived, 284, 289–90
 ρ -Nitrophenol
 sulfation of, 164
Nuclear magnetic resonance (NMR)
 receptor studies using, 1, 6–12

O

Opioid receptors, 389–415
 Ca^{2+} mobilization and, 395–97
 G protein–adenylate cyclase pathway, 390–93
 ion channels and, 393–95
 MAP kinase cascades and, 397–99
 phospholipid C pathway and, 395–97
 receptor genes, 405–12
 gene concentration and pharmacological activities, 409–12
 gene structure, 407–9
 knockout mice, 389, 410–12
 mRNA levels, 405–7
 receptor phosphorylation, 399–405
 desensitization and, 399–403
 receptor internalization and down-regulation and, 403–5
 receptor structure, 389–99
 signaling, 389–415
 See also G protein-coupled receptors
Orexin receptors, 200–1
Orexins, 200–1
 feeding behavior and, 200–1
Osteoporosis treatment
 cathepsin K, 197–99
Oxidative phosphorylation, 353–78
 mitochondrial, 353, 357
 uncouplers of, 353–54, 357, 365–77
Oxidative stress
 hepatotoxicology and, 50, 55

P

Parallel-array synthesis, 273–75, 278–79

Parallel artificial membrane permeation assay (PAMPA), 140


PAS, 519–45

aryl hydrocarbon (Ah) receptor pathway and, 521–27
basic-helix-loop-helix (bHLH) proteins, 521
circadian response pathway, 533–37
domains, 519–45
hypoxia response pathway and, 527–33, 537
Permeability transition, 353, 356
 mitochondrial poisoning and, 356
Peroxisome proliferator-activated receptors (PPARs), 491–50
 cell growth and differentiation and, 492–509
 fatty acid metabolism and, 492–95, 509
 glucose homeostasis, 492–95, 509
 inflammation and, 491, 492–98, 509–9
 ligands, 495–99
 structure and function of isoforms, 492–95
Peroxisome proliferators (PPs), 491–510
 hepatocarcinogenesis induced by, 504–7
 oxidative-stress hypothesis, 504–6
 response elements, 499–500
Pharmacodynamics, 67–68, 72–90, 209–31, 649
 computer simulation clinical trials, 209, 212–31
 defined, 68
 modeling in drug development, 67–68, 72–90

- examples, 80–87
- future needs, 88–90
- uses, 78–80
- Pharmacogenetics
 - human genomics and, 97, 118–20
 - sulfotransferase, 159–71
- Pharmacokinetic/pharmacodynamic
 - drug action model, 212, 216, 218–31
 - modeling, 67–68, 72–90
 - drug development and, 67–68, 72–90
 - hierarchical model approach in, 76–77
- Pharmacokinetics
 - computer simulation clinical trials, 209, 212–31
 - defined, 68
 - drug-candidate screening and, 133, 144–47
 - HIV protease inhibitors and, 653–55, 657–70
 - in vitro screening, 144–45
 - in vivo screening, 145–47
 - modeling in drug development and, 67–68, 72–90
 - examples, 80–87
 - future needs, 88–90
 - uses, 78–80
 - species, strain, and sex differences, 19, 25–27
- Phenylpropylamine, 48
- Phospholipid metabolism
 - Rho and regulation of, 462, 466–67
- Phosphoserine, 617, 624–25
- Pirenzepine, 5
- Polymerase chain reaction, real-time (RT-PCR), 335, 337
- Positional scanning, 273, 276, 278–79
- Protein-protein interaction
 - 14-3-3 proteins and, 617–38
- Protein therapeutics, 187–88
- Proteomics, 177, 179–80, 193, 204–5
- P2X receptors, 563–75
 - ATP and, 563–75
 - heteromeric, 563, 573–75
 - homomeric, 563–73
- Pycnodysostosis, 198
- R**
- Reactive metabolites
 - chemical-induced hepatotoxicity and, 19, 27–30, 48–50
- Reactive oxygen species, 50, 355
- Real-time polymerase chain reaction (RT-PCR), 335, 337
- Receptor phosphorylation, 399–405
 - opioid
 - desensitization and, 399–403
 - receptor internalization and down-regulation, 403–5
- Receptors
 - aryl hydrocarbon (Ah), 521–27
 - early studies, 1, 3–14
 - G protein-coupled
 - cross-reactivity of ligands, 201–2
 - drug discovery targets, 178, 180, 183–85
 - gene superfamily, 199–202
 - melanin-concentrating hormone, 200–1
 - opioid receptors, 389–415
 - orexins, 200–1
 - receptor genes, 405–12
 - receptor phosphorylation, 399–405
 - receptor structure, 389–99
- muscarinic, 1–14
 - conformational variability, 1, 6–8
 - early studies, 1–14
 - specificity, 6–14
 - subtypes, 1
- nicotinic acetylcholine (nAChRs), 431–48
 - allosteric transitions of, 444–48
 - Monod-Wyman-Changeux theory, 447–48
 - nAChR oligomer, 432–33
 - nicotinic binding, 436–40
 - subunit structure, 433–36
 - transmembrane organization, 433–36
- opioid, 389–415
 - Ca²⁺ mobilization and, 395–97
 - G protein-adenylate cyclase pathway, 390–93
 - ion channels and, 393–95
 - MAP kinase cascades and, 397–99
 - phospholipid C pathway and, 395–97
 - receptor genes, 405–12
 - receptor phosphorylation, 399–405
 - receptor structure, 389–99
 - signaling, 389–415
- orexin, 200–1
- peroxisome proliferator-activated (PPARs), 491–50
 - cell growth and differentiation and, 492–509
 - fatty acid metabolism and, 492–95, 509
 - glucose homeostasis, 492–95, 509

- inflammation and, 491, 492-98, 509-9
 - ligands, 495-99
 - structure and function of isoforms, 492-95
 - P2X receptors, 563-75
 - ATP and, 563-75
 - heteromeric, 563, 573-75
 - homomeric, 563-73
 - Regeneration
 - hepatocellular, 43, 53-55
 - Regulator of G protein signaling (RGS) proteins, 235-62
 - chromosomal localization of, 244-45, 248-50
 - desensitization and, 246-48
 - discovery of RGS family, 237, 262
 - gene structure of, 244-45
 - G protein-coupled receptor signaling in various cell types and, 240-43
 - intracellular localization of, 248-50
 - links to other signaling pathways, 257-60
 - molecular structure of, 250-57
 - mutagenesis studies of GTPase activating proteins, 254-55
 - mRNAs of, 245-46
 - protein function, 237-40
 - protein structure, 252-53
 - Renal toxicity, 31
 - Reserpine
 - serotonin and norepinephrine release and, 24
 - Retroviral vectors
 - tetracycline-inducible, 295, 305-9
 - Rho family of proteins
 - G protein-coupled signal transduction and, 459-78
 - apoptosis and, 472-73
 - bacterial toxins and, 462-64
 - cell migration and, 468-69
 - cell proliferation and, 471
 - cytoskeleton and, 459, 464-66, 474
 - effectors, 464
 - gene transcription and, 469-71, 474
 - hypertrophic cell growth, 472
 - MAP kinase activation and, 469-71
 - phospholipid metabolism, 462, 466-67
 - regulators, 460-64
 - RhoA, 459-60, 465, 470, 472-74
 - RhoGAPs, 460
 - RhoGDI, 460, 462
 - RhoGEF, 459-61
 - smooth muscle contraction, 467-68, 474
 - tumor cell invasion and, 467-69
 - Ritonavir, 650-55, 657-69
 - Rule of Five, 149-50, 184
- S**
- Saquinavir, 650-60, 665-66
 - Schizophrenia
 - 5-HT₂ receptors and, 329-30
 - Scintillation proximity assays, 347-48
 - Screening
 - drug candidate screening
 - absorption potential assessment, 139-41
 - biotransformation, 147-49
 - blood-brain barrier, 141
 - computer modeling, 149-50
 - counterscreens, 136
 - criteria, 135-36
 - cytochromes P450, 141-44, 150
 - drug metabolism and, 133, 135-51
 - interpretation, 137
 - pharmacokinetics and, 133, 135-51
 - high-throughput (HTS), 133-51, 177, 180-84, 188, 193-205, 279, 335, 337
 - drug discovery and, 193-205
 - molecular toxicology drug screening, 335-50
 - branched DNA signal amplification, 337-38, 347-49
 - differential displays, 337-39
 - hybridization microarrays, 335, 337, 340-46
 - real-time polymerase chain reactions (RT-PCR), 335, 337, 347-49
 - scintillation proximity, 337-38, 347-49
 - serial analysis of gene expression (SAGE), 337-38, 346-47
 - subtractive hybridization, 337, 339-40
 - positional, 273, 276, 278-79
 - See also Drug candidate screening; High-throughput screening; Screening
 - Secreted factors
 - gene therapy and, 295, 298, 301-5, 309-11
 - angiogenesis and, 303-4
 - Selectin, 283-91
 - leukocyte-endothelium interaction in reperfusion injury, 284, 290-91

- P-Selectin glycoprotein
ligand-1, 289
- Selectin inhibitors, 283-91
protective action of, 283-84, 286-91
ischemia/reperfusion, 285-87
- Sequencing
expressed sequence tags (EST), 193-99, 205
shotgun, 98-98, 100
- Serial analysis of gene
expression (SAGE), 337-38, 346-47
- Serotonin, 319-30
5-HT₆ receptors, 319-30
sulfation of, 164
- Seven transmembrane receptors, 199-202
- Sialyl Lewis^x, 283, 286, 288-89
- Signal transduction
14-3-3 proteins and, 619, 628-36
G protein-coupled receptors, 389-415
opioid receptors, 389-415
Raf-1-mediated, 629-31
regulator of G protein signaling (RGS) proteins, 235-62
See also G protein-coupled signal transduction; Rho family of proteins
- Single nucleotide polymorphisms (SNP), 97, 102-18
cancer risk and, 106-17
in a coding region (cSNP), 102
disease prevention, diagnosis, and treatment strategies, 105
- Smooth muscle contraction
Rho and, 467-68, 474
- Snake venom α -toxins, 432
- Solid-phase peptide synthesis, 273-74, 278-79
- Spirolactone, 31
- Steatosis
chlorinated methanes and, 43-45, 47
mechanisms of action, 45
- Streptomyces lividans*
tetrameric potassium channel of, 443
- Structure-activity relationships, 183
- Subtractive hybridization, 337, 339-40
- Suicide enzyme inhibitors, 31-32
- Sulfotransferase, 159-71
classification, 162-65
gene expression, 165
nomenclature, 160, 170
SULT gene, 160-62
- Sulphonamides, 4
- SULT
See under Sulfotransferase
- Synteny, 121-23
comparative genomics and, 121-23
Down's syndrome and, 122-23
- T**
- TaqMan polymerase chain reaction, 179
- Target validation, 177-79, 188, 193-205
cathepsin K, 193, 197-99
EST sequencing, 193-96
novel protein sequences, 196-97
"smart" libraries, 194-96
- TCDD
differential display studies of, 338-39
- Tetracycline, 295, 305-9
- Tetracycline-inducible retroviral vectors, 295, 305-9
- Thalidomide, 26
- Thrombin, 459, 465, 468-69
- Toxic chemically reactive metabolites, 19, 27-30
- Tumor cell invasion
Rho and, 468-69
- Tumor growth suppression
peroxisome proliferators, 507-8
- Tumorigenesis
14-3-3 proteins and, 638
- Tumor necrosis factor
malaria and, 101
- U**
- Ubiquinone, 354-55, 360
- UDP-glucuronosyltransferases, 581-606
autoimmunity and, 581, 606
carcinogenesis and, 603-5
detoxification process, 581-83
extrahepatic gene expressions, 595-599
genoprotective role, 603-5
human, 587-606
inherited unconjugated hyperbilirubinemia, 599-600, 603
- Uncouplers, 353-54, 357, 365-77
- V**
- Vascular endothelial growth factor (VEGF), 303-5
gene delivery encoding angiogenic factors, 303-4
- X**
- Xenobiotic-induced bioenergetic failure, 353
- Xenobiotic metabolizing enzymes (XMEs), 521-27
- Xenobiotics
drug screening and, 335-50
- Z**
- Zipper mechanism, 7



CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 36-40

A

Acosta D Jr, 38:63-96
Alexander RW, 36:281-306
Allen JW, 39:151-73
Amara SG, 39:431-56
Ambudkar SV, 39:361-97
Anders MW, 38:501-37
Anderson SP, 40:491-518
Aposhian HV, 37:397-419
Aschner M, 39:151-73
Augustine GJ, 36:659-701

B

Baker RC, 39:127-50
Bakhle YS, 38:97-120
Balboa MA, 39:175-89
Balsinde J, 39:175-89
Barrett JC, 36:573-96
Bellamy WT, 36:161-83
Bennett CF, 36:107-29
Benovic JL, 38:289-319
Benowitz NL, 36:597-613
Bilsky EJ, 36:379-401
Black J, 36:1-33
Blackburn TP, 40:319-34
Blaschke TF, 37:451-75
Blau HM, 40:295-317
Borges K, 39:221-41
Borjigin J, 39:53-65
Botting RM, 38:97-120
Bradfield CA, 40:519-61
Branchek TA, 40:319-34
Brett CM, 38:431-60
Briggs JM, 37:71-90
Broder S, 40:97-132
Brown JH, 40:459-89

Burchiel SW, 36:131-59
Burgen ASV, 40:1-16
Burns ME, 36:659-701
Burt SK, 36:545-71

C

Catterall WA, 37:361-96
Changeux J-P, 40:431-58
Chaudhuri G, 37:477-515
Choudhuri S, 39:267-94
Clapham DE, 37:167-203
Collins MD, 39:399-430
Collman GW, 36:573-96
Conn PJ, 37:205-37
Corringer P-J, 40:431-58
Corton JC, 40:491-518
Costa E, 38:321-50
Costa LG, 38:21-43
Coyle JT, 36:83-106
Croke ST, 36:107-29
Croxatto HB, 36:47-81

D

Dalton TP, 39:67-101
Davila DR, 36:131-59
Davila JC, 38:63-96
DeBello WM, 36:659-701
Debouck C, 40:193-208
Dekant W, 38:501-37
Dennis EA, 39:175-89
Dessauer CW, 36:461-80
De Vries L, 40:235-71
Dey S, 39:361-97
Dingledine R, 39:221-41
Dray A, 36:253-80
Dunham EW, 37:53-69

E

Elenko E, 40:235-71
Elliott JD, 40:177-91
Erickson JW, 36:545-71
Evans CJ, 36:379-401
Exton JH, 36:481-509

F

Farquhar MG, 40:235-71
Felder CC, 38:179-200
Fischer T, 40:235-71
Fisher JW, 38:1-20
Flexner C, 40:651-76
Fu H, 40:619-49

G

Giacomini KM, 38:431-60
Gibbs JB, 37:143-66
Gillette JR, 40:19-41
Gilman AG, 36:461-80
Glass M, 38:179-200
Goldstein A, 37:1-28
Gottesman MM, 39:361-97
Griendling KK, 36:281-306
Gu Y-Z, 40:519-61
Gudermann T, 36:429-59
Guengerich FP, 39:1-17

H

Halmes NC, 37:91-117
Hammond HK, 39:343-60
Hefti F, 37:239-67
Heinrich M, 38:539-65
Hobbs AJ, 39:191-220
Hockerman GH, 37:361-96
Hoffman AR, 38:45-61

Hogenesch JB, 40:519-61
Holford NHG, 40:209-34
Holsapple MP, 36:131-59
Hosokawa M, 38:257-88
Houghten RA, 40:273-82
Hoyer PB, 36:307-31
Hrycyna CA, 39:361-97
Huff J, 36:573-96

I

Insel PA, 39:175-89, 343-60
Ito K, 38:461-99
Iwatsubo T, 38:461-99

J

Joad JP, 37:29-52
Johnson BD, 37:361-96
Johnson DG, 39:295-312

K

Kalkbrenner F, 36:429-59
Kaminski NE, 36:131-59
Kanamitsu S, 38:461-99
Karras JG, 36:131-59
Kastrissios H, 37:451-75
Kimmelberg HK, 39:151-73
Kimko HC, 40:209-34
Klaassen CD, 39:267-94
Kobilka BK, 38:351-73
Kramer RE, 39:127-50
Krupnick JG, 38:289-319

L

Lai J, 36:379-401
Lasségue B, 36:281-306
Lau SS, 38:229-55
Law P-Y, 40:389-430
Ledbetter JA, 36:131-59
Lefer DJ, 40:283-94
Lemasters JJ, 37:327-38
Le Moal M, 36:359-78
Le Novère N, 40:431-58
Li C, 36:185-201
Li X, 39:53-65
Liehr JG, 36:203-32
Lipton SA, 38:159-77
Liu J, 39:267-94

Loh HH, 40:389-430
LoPachin RM, 39:151-73
Lukas SE, 36:333-57

M

Maines MD, 37:517-54
Mao GE, 39:399-430
Marcus R, 38:45-61
Marrone TJ, 37:71-90
Masters SC, 40:619-49
McCammon JA, 37:71-90
Melchert RB, 38:63-96
Metcalf B, 40:193-208
Meyer UA, 37:269-96
Miller RJ, 38:201-27
Moncada S, 39:191-220
Monks TJ, 38:229-55
Monteleone JPR, 40:209-34
Myers MG Jr, 36:615-58
Myers SJ, 39:221-41

N

Nagata K, 40:159-76
Nakajima Y, 38:461-99
Nathan L, 37:477-515
Neal RA, 36:35-46
Neer EJ, 37:167-203
North RA, 40:563-80

O

Ohlstein EH, 40:177-91
Oliff A, 37:143-66
Ortiz de Montellano BR,
38:539-65
Otterness DM, 39:19-52
Ozawa CR, 40:295-317

P

Pastan I, 39:361-97
Peck CC, 40:209-34
Peoples RW, 36:185-201
Peterson BZ, 37:361-96
Pettit DL, 36:659-701
Piazza PV, 36:359-78
Pin J-P, 37:205-37
Pinkerton KE, 37:29-52

Plaa GL, 40:43-65
Polson JB, 36:403-27
Porreca F, 36:379-401
Post SR, 39:343-60
Pratt WB, 37:297-326
Puga A, 39:67-101
Pumford NR, 37:91-117

R

Ramachandra M, 39:361-97
Ramos KS, 39:243-65
Regunathan S, 36:511-44
Reis DJ, 36:511-44
Robbins A, 36:47-81
Robles M, 38:539-65
Rodan GA, 38:375-88
Rodriguez E, 38:539-65
Rodriguez RJ, 38:63-96
Rohrer DK, 38:351-73
Ruffolo RR Jr, 40:177-91

S

Safe SH, 38:121-58
Sagi SA, 40:459-89
Sah VP, 40:459-89
Satoh T, 38:257-88
Schatz AR, 36:131-59
Schieven GL, 36:131-59
Schultz G, 36:429-59
Schweizer FE, 36:659-701
Seal RP, 39:431-56
Seasholtz TM, 40:459-89
Sheiner L, 40:67-96
Shertzer HG, 39:67-101
Sibley DR, 39:313-41
Simonian NA, 36:83-106
Sipes IG, 36:307-31
Snyder SH, 39:53-65
Spitz IM, 36:47-81
Springer ML, 40:295-317
Starkov AA, 40:353-88
Stauber A, 40:491-518
Steimer J-L, 40:67-96
Strada SJ, 36:403-27
Strassburg CP, 40:581-618
Streit WJ, 39:151-73
Strosberg AD, 37:421-50

Stuehr DJ, 37:339-59

Subramanian RR, 40:619-49

Sugiyama Y, 38:461-99

Sunahara RK, 36:461-80

Surprenant A, 40:563-80

Szumslanski CL, 39:19-52

T

Thummel KE, 38:389-430

Thurman RG, 37:327-38

Tukey RH, 40:581-618

U

Ulrich RG, 40:335-52

Urban L, 36:253-80

V

Vanderah TW, 36:379-401

Vane JR, 38:97-120

Venter JC, 40:97-132

W

Walker CL, 39:295-312

Wallace KB, 40:353-88

Waring JF, 40:335-52

Wei L-N, 37:119-41

Weight FF, 36:185-201

Weinshilboum RM, 39:19-

52

West JE, 38:539-65

White MF, 36:615-58

White RE, 40:133-57

Whitlock JP Jr, 39:103-25

Wilkinson GR, 38:389-430

Witschi H, 37:29-52

Wolff MS, 36:573-96

Wong YH, 40:389-430

Woosley RL, 36:233-52

Y

Yager JD, 36:203-32

Yamazoe Y, 40:159-76

Z

Zaki PA, 36:379-401

Zanger UM, 37:269-96

Zhang L, 38:431-60

Zheng B, 40:235-71

Zimmerman BG, 37:53-69

CHAPTER TITLES, VOLUMES 36-40

PREFATORY

Pharmacology

A Personal View of Pharmacology	J Black	36:1-33
A Rewarding Research Pathway	A Goldstein	37:1-28
A Quest for Erythropoietin Over Nine Decades	JW Fisher	38:1-20
Targets of Drug Action	A Burgen	40:1-16

Toxicology

A Career in Toxicology	RA Neal	36:35-46
Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Institute, NIH: A Short History	JR Gillette	40:19-41
Chlorinated Methanes and Liver Injury: Highlights of the Past 50 Years	GL Plaa	40:43-65

GENERAL TOPICS IN PHARMACOLOGY AND TOXICOLOGY

Receptors

Angiotensin Receptors and Their Therapeutic Implications	KK Griendling, B Lasségue, RW Alexander	36:281-306
Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators	JC Corton, SP Anderson, A Stauber	40:491-518
Opioid Receptor Types and Subtypes: The δ Receptor as a Model	PA Zaki, EJ Bilsky, TW Vanderah, J Lai, CJ Evans, F Porreca	36:379-401
Diversity and Selectivity of Receptor-G Protein Interaction	T Gudermann, F Kalkbrenner, G Schultz	36:429-59
Imidazoline Receptors and Their Endogenous Ligands	S Regunathan, DJ Reis	36:511-44
Pharmacology and Functions of Metabotropic Glutamate Receptors	PJ Conn, J-P Pin	37:205-37
The Role of the hsp90-Based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling via Map Kinase	WB Pratt	37:297-326
Structure and Function of the β_1 -Adrenergic Receptor	AD Strosberg	37:421-50
Cannabinoid Receptors and Their Endogenous Agonists	CC Felder, M Glass	38:179-200
Presynaptic Receptors	RJ Miller	38:201-27
From GABAA Receptor Diversity Emerges A Unified Vision of GABAergic Inhibition	E Costa	38:321-50
Insights from In Vivo Modification of Adrenergic Receptor Gene Expression	DK Rohrer, BK Kobilka	38:351-73

Genetic Regulation of Glutamate Receptor Ion Channels	SJ Myers, R Dingledine, K Borges	39:221-41
New Insights into Dopaminergic Receptor Function Using Antisense and Genetically Altered Animals	DR Sibley	39:313-41
5-HT ₆ Receptors as Emerging Targets for Drug Discovery	TA Branchek, TP Blackburn	40:319-34
Nicotinic Receptors at the Amino Acid Level	P-J Corringer, N Le Nov��re, J-P Changeux	40:431-58
Pharmacology of Cloned P2X Receptors	RA North, A Surprenant	40:563-80
<i>Synaptic Functions</i>		
Insulin Signal Transduction and the IRS Proteins	MG Myers Jr, MF White	36:615-58
Exocytosis: Proteins and Perturbations	GJ Augustine, ME Burns, WM DeBello, DL Pettit, FE Schweizer	36:659-701
Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels	GH Hockerman, BZ Peterson, BD Johnson, WA Catterall	37:361-96
Signal Transduction in Environmental Neurotoxicity	LG Costa	38:21-43
Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target	AJ Hobbs, A Higgs, S Moncada	39:191-220
Redox Regulation of <i>c-Ha-ras</i> and Osteopontin Signaling in Vascular Smooth Muscle Cells: Implications in Chemical Atherogenesis	KS Ramos	39:243-65
Cyclins and Cell Cycle Checkpoints	DG Johnson, CL Walker	39:295-312
The Regulator of G Protein Signaling Family	L De Vries, B Zheng, T Fischer, E Elenko, MG Farquhar	40:235-71
Pharmacology of Selectin Inhibitors in Ischemia/Reperfusion States	DJ Lefer	40:283-94
The Role of Rho in G Protein Coupled Receptor Signal Transduction	VP Sah, TM Seasholtz, SA Sagi, JH Brown	40:459-89
14-3-3 Proteins: Structure, Function, and Regulations	H Fu, RR Subramanian, SC Masters	40:619-49
<i>Enzymes</i>		
Complexity and Diversity of Mammalian Adenylyl Cyclases	RK Sunahara, CW Dessauer, AG Gilman	36:461-80
Regulation of Phosphoinositide Phospholipases by Hormones, Neurotransmitters, and Other Agonists Linked to G Proteins	JH Exton	36:481-509
The Heme Oxygenase System: A Regulator of Second-Messenger Gases	MD Maines	37:517-54
The Mammalian Carboxylesterases: From Molecules to Functions	T Satoh, M Hosokawa	38:257-88
The Role of Receptor Kinases and Arrestins in G Protein-Coupled Receptor Regulation	JG Krupnick, JL Benovic	38:289-319
Methylation Pharmacogenetics: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase	RM Weinshilboum, DM Otterness, CL Szumlanski	39:19-52
Regulation and Inhibition of Phospholipase A ₂	J Balsinde, MA Balboa, PA Insel, EA Dennis	39:175-89
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease	RH Tukey, CP Strassburg	40:581-618

Chemical Agents

Progress in Antisense Oligonucleotide Therapeutics	ST Crooke, CF Bennett	36:107-29
Pharmacology of Nicotine: Addiction and Therapeutics	NL Benowitz	36:597-613
Protein Targets of Xenobiotic Reactive Intermediates	NR Pumford, NC Halmes	37:91-117
G Protein Beta-Gamma Subunits	DE Clapham, EJ Neer	37:167-203
Pharmacology of Neurotrophic Factors	F Hefti	37:239-67
Structure-Function Aspects in the Nitric Oxide Synthases	DJ Stuehr	37:339-59
Enzymatic Methylation of Arsenic Species and Other New Approaches to Arsenic Toxicity	HV Aposhian	37:397-419
The Pharmacology and Toxicology of Polyphenolic-Glutathione Conjugates	TJ Monks, SS Lau	38:229-55
Ethnopharmacology of Mexican Asteraceae (Compositae)	M Heinrich, M Robles, JE West, BR Ortiz de Montellano, E Rodriguez	38:539-65
The Pineal Gland and Melatonin: Molecular and Pharmacologic Regulation	J Borjigin, X Li, SH Snyder	39:53-65
Regulation of Gene Expression by Reactive Oxygen	TP Dalton, HG Shertzer, A Puga	39:67-101
Cytotoxicity of Short-Chain Alcohols	RC Baker, RE Kramer	39:127-50
Metallothionein: An Intracellular Protein to Protect Against Cadmium Toxicity	CD Klaassen, J Liu, S Choudhuri	39:267-94
Teratology of Retinoids	MD Collins, GE Mao	39:399-430

Biotransformation

Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism	UA Meyer, UM Zanger	37:269-96
In Vitro and In Vivo Drug Interactions Involving Human CYP3A	KE Thummel, GR Wilkinson	38:389-430
Glutathione-Dependent Bioactivation of Haloalkenes	MW Anders, W Dekant	38:501-37
Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism	FP Guengerich	39:1-17
Induction of Cytochrome P4501A1	JP Whitlock Jr	39:103-25

Pharmacokinetics/Toxicokinetics

Role of Organic Cation Transporters in Drug Absorption and Elimination	L Zhang, CM Brett, KM Giacomini	38:431-60
Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter	SV Ambudkar, S Dey, CA Hrycyna, M Ramachandra, I Pastan, MM Gottesman	39:361-97
Mitochondrial Targets of Drug Toxicity	KB Wallace, AA Starkov	40:353-88

Cancer and Carcinogenesis

P-Glycoproteins and Multidrug Resistance	WT Bellamy	36:161-83
Molecular Mechanisms of Estrogen Carcinogenesis	JD Yager, JG Liehr	36:203-32
The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics	JB Gibbs, A Oliff	37:143-66
Interactions Between Hormones and Chemicals in Breast Cancer	SH Safe	38:121-58

Clinical Therapeutics

Medication Compliance as a Feature in Drug Development	H Kastrissios, TF Blaschke	37:451-75
Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical Benefits	C Flexner	40:651-76

Drug Development Science

Structure-Based Drug Design: Computational Advances	TJ Marrone, JM Briggs, JA McCammon	37:71-90
Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millennium	RA Houghten	40:273-82
A Novel Means of Drug Delivery: Myoblast-Mediated Gene Therapy and Regulatable Retroviral Vectors	CR Ozawa, ML Springer, HM Blau	40:295-317

SYSTEMS

Immune System/Inflammation

Molecular Mechanisms of Toxicant-Induced Immunosuppression: Role of Second Messengers	MP Holsapple, JG Karras, JA Ledbetter, GL Schieven, SW Burchiel, DR Davila, AR Schatz, NE Kaminski	36:131-59
Cyclooxygenases 1 and 2	JR Vane, YS Bakhle, RM Botting	38:97-120

Central Nervous System

Oxidative Stress in Neurodegenerative Diseases	NA Simonian, JT Coyle	36:83-106
Lipid vs Protein Theories of Alcohol Action in the Nervous System	RW Peoples, C Li, FF Weight	36:185-201
New Pharmacological Strategies for Pain Relief	A Dray, L Urban	36:253-80
CNS Effects and Abuse Liability of Anabolic-Androgenic Steroids	SE Lukas	36:333-57
Pathophysiological Basis of Vulnerability to Drug Abuse: Role of an Interaction Between Stress, Glucocorticoids, and Dopaminergic Neurons	PV Piazza, M Le Moal	36:359-78
Glial Cells in Neurotoxicity Development	M Aschner, JW Allen, HK Kimelberg, RM LoPachin, WJ Streit	39:151-73
Excitatory Amino Acid Transporters: A Family in Flux	RP Seal, SG Amara	39:431-56
Molecular Mechanisms and Regulation of Opioid Receptor Signaling	P-Y Law, YH Wong, HH Loh	40:389-430

Autonomic Nervous System

β -Adrenergic Receptors and Receptor Signaling in Heart Failure	SR Post, HK Hammond, PA Insel	39:343-60
---	----------------------------------	-----------

Cardiovascular System

Cardiac Actions of Antihistamines	RL Woosley	36:233-52
Cyclic Nucleotide Phosphodiesterases and Vascular Smooth Muscle	JB Polson, SJ Strada	36:403-27
Tissue Renin-Angiotensin Systems: A Site of Drug Action?	BG Zimmerman, EW Dunham	37:53-69
Reperfusion Injury After Liver Preservation for Transplantation	JJ Lemasters, RG Thurman	37:327-38

Endocrine System

Antiprogestins: Mechanism of Action and Contraceptive Potential	IM Spitz, HB Croxatto, A Robbins	36:47-81
Assessment of Follicle Destruction in Chemical-Induced Ovarian Toxicity	PB Hoyer, IG Sipes	36:307-31
Estrogens and Atherosclerosis	L Nathan, G Chaudhuri	37:477-515

Growth Hormone As Therapy for Older Men and Women	R Marcus, AR Hoffman	38:45-61
Mechanism of Action of Biophosphates	GA Rodan	38:375-88
<i>Pulmonary System</i>		
The Toxicology of Environmental Tobacco Smoke	H Witschi, JP Joad, KE Pinkerton	37:29-52
<i>Microbial Systems</i>		
Structural Mechanisms of HIV Drug Resistance	JW Erickson, SK Burt	36:545-71
Neuronal Injury Associated with HIV-1: Approaches to Treatment	SA Lipton	38:159-77
MISCELLANEOUS		
<i>Techniques</i>		
Transgenic Animals as New Approaches in Pharmacological Studies	L-N Wei	37:119-41
Predictive Value of In Vitro Model Systems in Toxicology	JC Davila, RJ Rodriguez, RB Melchert, D Acosta Jr	38:63-96
Quantitative Prediction of In Vivo Drug Clearance and Drug Interactions from In Vitro Data on Metabolism, and Together with Binding and Transport	K Ito, T Iwatsubo, S Kanamitsu, Y Nakajima, Y Sugiyama	38:461-99
The Impact of Genomics-Based Technologies on Drug Safety Evaluation	JF Waring, RG Ulrich	40:335-52
<i>Environmental Toxicity</i>		
The PAS Superfamily: Sensors of Environmental and Developmental Signals	Y-Z Gu, JB Hogenesch, CA Bradfield	40:519-61
<i>Risk Assessment</i>		
Breast Cancer and Environmental Risk Factors: Epidemiological and Experimental Findings	MS Wolff, GW Collman, JC Barrett, J Huff	36:573-96
PHARMACOLOGY AND TOXICOLOGY IN THE NEW MILLENNIUM		
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development	LB Sheiner, J-L Steimer	40:67-96
Sequencing the Entire Genomes of Free-Living Organisms: The Foundation of Pharmacology in the New Millenium	S Broder, JC Venter	40:97-132
High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery	RE White	40:133-57
Pharmacogenetics of Sulfotransferase	K Nagata, Y Yamazoe	40:159-76
Drug Discovery in the Next Millennium	EH Ohlstein, RR Ruffolo Jr, JD Elliott	40:177-91
The Impact of Genomics on Drug Discovery	C Deboucq, B Metcalf	40:193-208
Simulation of Clinical Trials	NHG Holford, HC Kimko, JPR Monteleone, CC Peck	40:209-34

